Pretreatment drug, n (%) | 2013 (N = 47) | 2014 (N = 96) | 2015 (N = 23) | 2016 (N = 8) | 2017 (N = 7) | Total (N = 181) |
---|---|---|---|---|---|---|
Artemether (intramuscular) | 1 (2.1) | 0 | 0 | 0 | 0 | 1 (0.6) |
Artesunate (intravenous) | 0 | 2 (2.1) | 2 (8.7) | 0 | 0 | 4 (2.2) |
Chloroquine | 3 (6.4) | 1 (1.0) | 0 | 0 | 0 | 4 (2.2) |
Artemether–lumefantrine | 34 (72.3) | 67 (69.8) | 6 (26.1) | 7 (85.7) | 6 (85.7) | 120 (66.3) |
Sulfadoxine–pyrimethamine | 2 (4.3) | 5 (5.2) | 1 (4.4) | 0 | 0 | 8 (4.4) |
Quinine | 6 (12.8) | 6 (6.3) | 1 (4.4) | 1 (14.3) | 0 | 14 (7.7) |
Artesunate and artemether lumefantrine | 0 | 1 (1.0) | 0 | 0 | 0 | 1 (0.6) |
Artemether–lumefantrine and sulfadoxine–pyrimethamine | 0 | 1 (1.0) | 0 | 0 | 0 | 1 (0.6) |
Artemether–lumefantrine and quinine | 0 | 3 (3.1) | 0 | 0 | 0 | 3 (1.7) |
Unknown | 1 (2.1) | 10 (10.4) | 13 (57.0) | 0 | 1 (14.3) | 25 (13.8) |